PS2:28 Autoantibody profiling in prostvac and ipilimumab treated prostate cancer patients reveals potential biomarkers of immune-related adverse events
Poster session 2: Autoantibodies, biomarkers and imaging (2), Environmental, epigenetics and genomics
PS2:28 Autoantibody profiling in prostvac and ipilimumab treated prostate cancer patients reveals potential biomarkers of immune-related adverse events